The 44th Union World Conference on Lung Health and the Centers for Disease Control and Prevention, Atlanta, Georgia, USA are pleased to co-sponsor the TB Late-breaker session. The session will feature seven interesting presentations from around the world. Each presentation will be 10 minutes in length, followed by 5 minutes discussion time. Copies of the presentation abstracts will be available at the session. We look forward to seeing you there and to having a stimulating discussion around these issues.

Centers for Disease Control and Prevention (CDC): Sarita Shah
The International Union Against Tuberculosis and Lung Diseases (The Union): Chinnambedu N. Paramasivan

09:15-09:30 Preventing adverse outcomes in patients suspected with smear negative TB: a randomized clinical trial of GeneXpert MTB/RIF testing in primary care clinics in Harare, Zimbabwe

09:30-09:45 A novel TB diagnostic algorithm using automated microscopy achieves high sensitivity while reducing the volume of Xpert MTB/RIF testing
Ismael N, Omar SV, Dowdy D, Clark D, v/d Meulen D, Kennedy S, Churchyard G (South Africa/USA)

09:45-10:00 Point-of-care test for TB based on immunodominant peptides of M. tb cell-wall proteins
Gonzalez JM, Francis B, Burda ST, Niedbala RS, Laal S (USA)

10:00-10:15 Intranasal immunization with influenza vector expressing two mycobacterium antigens enhances protective effect of BCG vaccination
Shurygina AP, Zabolotnyh N, Vinogradova T, Samsyzbay A, Khairullin B, Sandybayev N, Vitovskaia M, Stukova M (Russian Federation, Kazakhstan)

10:15-10:30 Microbiological efficacy and safety profile of Bedaquilline (TMC207) in the treatment of multidrug-resistant tuberculosis: interim analysis of a cohort of MDR/XDR patients
Guglielmetti L, Robert J, Le Dû D, Fréchet-Jachym M, Martin D, Métivier N (France)

10:30-10:45 A multicentre randomised controlled clinical trial to evaluate the toxicity of high dose rifampicin in the treatment of pulmonary tuberculosis (RIFATOX)

10:45-11:00 A randomized controlled trial of 4-month Gatifloxacin-containing regimen vs. standard 6-month regimen for treating drug-susceptible pulmonary tuberculosis: main efficacy and safety results of the OFLOTUB Trial

11:00-11:15 Discussion